JP2012520470A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012520470A5 JP2012520470A5 JP2011554260A JP2011554260A JP2012520470A5 JP 2012520470 A5 JP2012520470 A5 JP 2012520470A5 JP 2011554260 A JP2011554260 A JP 2011554260A JP 2011554260 A JP2011554260 A JP 2011554260A JP 2012520470 A5 JP2012520470 A5 JP 2012520470A5
- Authority
- JP
- Japan
- Prior art keywords
- snap
- endopeptidase
- cells
- retargeting
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 description 40
- 102000005593 Endopeptidases Human genes 0.000 description 28
- 108010059378 Endopeptidases Proteins 0.000 description 28
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 28
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 28
- 230000000694 effects Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000007248 cellular mechanism Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 229940066758 endopeptidases Drugs 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000028023 exocytosis Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 241000257465 Echinoidea Species 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16021709P | 2009-03-13 | 2009-03-13 | |
| US61/160,217 | 2009-03-13 | ||
| PCT/US2010/027244 WO2010105236A1 (en) | 2009-03-13 | 2010-03-12 | Immuno-based retargeted endopeptidase activity assays |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015203102A Division JP6254132B2 (ja) | 2009-03-13 | 2015-10-14 | 免疫系調節エンドペプチターゼ活性アッセイ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012520470A JP2012520470A (ja) | 2012-09-06 |
| JP2012520470A5 true JP2012520470A5 (enExample) | 2013-05-16 |
| JP5826635B2 JP5826635B2 (ja) | 2015-12-02 |
Family
ID=42244384
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011554260A Expired - Fee Related JP5826635B2 (ja) | 2009-03-13 | 2010-03-12 | 免疫系調節エンドペプチターゼ活性アッセイ |
| JP2015203102A Expired - Fee Related JP6254132B2 (ja) | 2009-03-13 | 2015-10-14 | 免疫系調節エンドペプチターゼ活性アッセイ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015203102A Expired - Fee Related JP6254132B2 (ja) | 2009-03-13 | 2015-10-14 | 免疫系調節エンドペプチターゼ活性アッセイ |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US8455203B2 (enExample) |
| EP (4) | EP2568285B1 (enExample) |
| JP (2) | JP5826635B2 (enExample) |
| KR (2) | KR101923847B1 (enExample) |
| CN (1) | CN102422158B (enExample) |
| AU (1) | AU2010223912B2 (enExample) |
| BR (1) | BRPI1009115A2 (enExample) |
| CA (1) | CA2753894C (enExample) |
| CL (1) | CL2011002274A1 (enExample) |
| CY (1) | CY1122573T1 (enExample) |
| DK (2) | DK3281953T3 (enExample) |
| ES (2) | ES2770033T3 (enExample) |
| HU (1) | HUE047067T2 (enExample) |
| IL (1) | IL214793A (enExample) |
| MX (1) | MX2011009606A (enExample) |
| MY (1) | MY156334A (enExample) |
| PH (1) | PH12015500992A1 (enExample) |
| PL (2) | PL2406629T3 (enExample) |
| PT (1) | PT3281953T (enExample) |
| RU (1) | RU2543650C2 (enExample) |
| SG (1) | SG174353A1 (enExample) |
| SI (1) | SI3281953T1 (enExample) |
| UA (1) | UA104456C2 (enExample) |
| WO (1) | WO2010105236A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8778634B2 (en) * | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| AU2011202219B2 (en) * | 2005-12-01 | 2015-05-28 | Allergan Inc. | Fusion proteins |
| GB0610867D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| KR101604515B1 (ko) * | 2008-03-14 | 2016-03-17 | 알러간, 인코포레이티드 | 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정 |
| AU2009223161B2 (en) | 2008-03-14 | 2014-10-30 | Allergan, Inc. | Immuno-based botulinum toxin serotype A activity assays |
| NZ594702A (en) | 2009-03-13 | 2013-05-31 | Allergan Inc | The SiMA cell line used for immuno-based or gene expression Botulinum Serotype A activity assays |
| EP2568285B1 (en) * | 2009-03-13 | 2019-12-25 | Allergan, Inc. | Immuno-based retargeted endopeptidase activity assays |
| US8129139B2 (en) | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
| US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
| EP2798077A2 (en) | 2011-12-31 | 2014-11-05 | Allergan, Inc. | Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A |
| US20140056870A1 (en) * | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
| US20170327810A1 (en) * | 2012-08-27 | 2017-11-16 | Ipsen Bioinnovation Limited | Fusion proteins and methods for treating, preventing or ameliorating pain |
| US9005628B2 (en) * | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
| WO2014059434A1 (en) * | 2012-10-12 | 2014-04-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Assay for analyses of rabies virus glycoprotein |
| EP3008204B1 (en) * | 2013-06-10 | 2024-03-13 | Iogenetics, LLC. | Mathematical processes for determination of peptidase cleavage |
| ES2829612T3 (es) * | 2013-10-25 | 2021-06-01 | Biomadison Inc | Ensayo enzimático con fluoróforos duplicados |
| US10408837B2 (en) * | 2013-12-09 | 2019-09-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Peptide substrates recognizable by type E botulinum neurotoxin |
| US9216210B2 (en) | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
| JP6738739B2 (ja) | 2014-04-30 | 2020-08-12 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 膀胱内滴下注入用生物製剤 |
| AU2015287964A1 (en) * | 2014-07-07 | 2017-02-16 | Allergan, Inc. | Method of detecting cleaved SNAP25 in tissue samples |
| CN107001451A (zh) * | 2014-07-07 | 2017-08-01 | 阿勒根公司 | 检测组织样品中裂解的snap25的方法 |
| SG11201700736YA (en) | 2014-07-31 | 2017-02-27 | Allergan Inc | Formulations of biologics for intravesical instillation |
| HUE046449T2 (hu) | 2016-09-13 | 2020-03-30 | Allergan Inc | Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények |
| CN106908610B (zh) * | 2017-03-13 | 2018-11-02 | 绍兴康知生物科技有限公司 | 一种基于受体配体结合技术筛查吸食吗啡的试剂、制备方法及应用 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| US5747641A (en) | 1989-12-21 | 1998-05-05 | Biogen Inc | Tat-derived transport polypeptide conjugates |
| CA2076386C (en) | 1990-02-26 | 2003-04-22 | David S. Hogness | Identification and expression of insect steroid receptor dna sequence |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
| US5364791A (en) | 1992-05-14 | 1994-11-15 | Elisabetta Vegeto | Progesterone receptor having C. terminal hormone binding domain truncations |
| EP0745121B1 (en) | 1992-05-14 | 2007-06-20 | Baylor College Of Medicine | Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy |
| US6432652B1 (en) | 1992-08-13 | 2002-08-13 | The Regents Of The University Of California | Methods of screening modulators of opioid receptor activity |
| US20020061554A1 (en) | 1992-08-13 | 2002-05-23 | Evans Christopher J. | Orphan opioid receptor and recombinant materials for its production |
| JP4208960B2 (ja) | 1992-08-13 | 2009-01-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | オピオイドレセプター遺伝子 |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| SE9304060D0 (sv) | 1993-12-06 | 1993-12-06 | Bioinvent Int Ab | Sätt att selektera specifika bakteriofager |
| GB9411138D0 (en) * | 1994-06-03 | 1994-07-27 | Microbiological Res Authority | Toxin assay |
| US5962637A (en) | 1994-06-03 | 1999-10-05 | Microbiological Research Authority | Toxin assay |
| US6495518B1 (en) | 1994-06-13 | 2002-12-17 | Vanderbilt University | Method for importing biologically active molecules into cells |
| US5807746A (en) | 1994-06-13 | 1998-09-15 | Vanderbilt University | Method for importing biologically active molecules into cells |
| GB9500851D0 (en) | 1995-01-17 | 1995-03-08 | Bionvent International Ab | Method of selecting specific bacteriophages |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| FR2739621B1 (fr) | 1995-10-05 | 1997-12-05 | Centre Nat Rech Scient | Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives |
| US6072041A (en) | 1996-06-03 | 2000-06-06 | Case Western Reserve University | Fusion proteins for protein delivery |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| DE19702280A1 (de) | 1997-01-23 | 1998-07-30 | Bosch Gmbh Robert | Verfahren zur Regelung der Leistungsverstärkung |
| ES2210761T3 (es) | 1997-05-21 | 2004-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas. |
| US6248558B1 (en) | 1998-03-31 | 2001-06-19 | Vanderbilt University | Sequence and method for genetic engineering of proteins with cell membrane translocating activity |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| CA2354044A1 (en) | 1998-12-10 | 2000-06-15 | Washington University | Protein transduction system and methods of use thereof |
| US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
| CA2369336A1 (en) | 1999-04-22 | 2000-11-02 | Cygnus, Inc. | Hydrogel in an iontophoretic device to measure glucose |
| US7034132B2 (en) | 2001-06-04 | 2006-04-25 | Anderson David W | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| EP1700918B1 (en) | 1999-08-25 | 2014-01-15 | Allergan, Inc. | Activatable recombinant neurotoxins |
| US20030180289A1 (en) | 1999-09-23 | 2003-09-25 | Foster Keith Alan | Inhibition of secretion from non-neuronal cells |
| US20030008813A1 (en) | 1999-12-17 | 2003-01-09 | Felgner Philip L. | Intracellular protein delivery compositions and methods of use |
| GB9930519D0 (en) | 1999-12-24 | 2000-02-16 | Phogen Limited | Uses of transport proteins |
| US7138127B1 (en) | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
| US6500436B2 (en) | 2000-01-19 | 2002-12-31 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
| WO2001054732A1 (en) | 2000-01-27 | 2001-08-02 | Genetics Institute, Llc. | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| US6903187B1 (en) * | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
| US20040219619A1 (en) | 2000-07-21 | 2004-11-04 | Ester Fernandez-Salas | Methods of identifying compounds that alter toxin persistence and/or protease activity |
| US6841535B2 (en) | 2000-07-31 | 2005-01-11 | Active Motif | Peptide-mediated transfection agents and methods of use |
| EE04529B1 (et) | 2001-03-16 | 2005-08-15 | Tartu �likool | Termofiilne mikroorganismi tüvi Bacillus coagulans SIM-7 DSM 14043 ja meetod L(+)-laktaadi tootmiseks fermenteeritavatest suhkrutest ja nende segudest nimetatud mikroorganismi tüve abil |
| US8022172B2 (en) | 2001-08-28 | 2011-09-20 | Allergan, Inc. | Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity |
| US7208285B2 (en) | 2001-08-28 | 2007-04-24 | Allergan, Inc. | Fret protease assays for botulinum serotype A/E toxins |
| US7374896B2 (en) * | 2001-08-28 | 2008-05-20 | Allergan, Inc. | GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity |
| US7332567B2 (en) | 2001-08-28 | 2008-02-19 | Allergan, Inc. | Fret protease assays for clostridial toxins |
| US20040057958A1 (en) | 2002-05-17 | 2004-03-25 | Waggoner David W. | Immunogenicity-enhancing carriers and compositions thereof and methods of using the same |
| RU2230325C2 (ru) * | 2002-08-15 | 2004-06-10 | Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации | Способ приготовления очищенного препарата ботулинического токсина типа а |
| US7183066B2 (en) | 2002-09-27 | 2007-02-27 | Allergan, Inc. | Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins |
| US7166692B2 (en) | 2003-03-04 | 2007-01-23 | Canbrex Bio Science Walkersville, Inc. | Intracellular delivery of small molecules, proteins, and nucleic acids |
| GB0321344D0 (en) | 2003-09-11 | 2003-10-15 | Health Prot Agency | Re-targeted toxin conjugates |
| JP4262072B2 (ja) | 2003-12-05 | 2009-05-13 | 株式会社日立製作所 | 自動車用補助機器制御装置 |
| EP1751284A4 (en) * | 2003-12-19 | 2010-01-13 | Wisconsin Alumni Res Found | METHOD AND COMPOSITIONS FOR DETECTING BOTULINUM NEUROTOXINE |
| DK1718756T3 (da) | 2004-02-24 | 2012-02-27 | Allergan Inc | Botulinumtoksinscreeningassays |
| WO2006011966A1 (en) | 2004-06-30 | 2006-02-02 | Allergan, Inc. | Optimizing expression of active botulinum toxin type e |
| US7514088B2 (en) | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| US7811584B2 (en) | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
| CA2575994A1 (en) | 2004-08-04 | 2006-02-16 | Allergan, Inc. | Optimizing expression of active botulinum toxin type a |
| WO2006026780A1 (en) * | 2004-09-01 | 2006-03-09 | Allergan, Inc. | Degradable clostridial toxins |
| US7399607B2 (en) | 2004-09-22 | 2008-07-15 | Allergan, Inc. | Fluorescence polarization assays for determining clostridial toxin activity |
| US20070258992A1 (en) | 2004-10-06 | 2007-11-08 | Atassi M Zouhair | Determining and Reducing Immunoresistance to Botulinum Toxin Therapy Using Botulinum Toxin a Peptides |
| AU2005311086B2 (en) | 2004-12-01 | 2012-03-29 | Allergan, Inc. | Fusion proteins |
| GB0426394D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US7659092B2 (en) | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
| CA2588292C (en) | 2004-12-01 | 2019-01-15 | Health Protection Agency | Non-cytotoxic protein conjugates |
| US8603779B2 (en) * | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| GB0426397D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US8512984B2 (en) * | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| US8021859B2 (en) * | 2005-03-15 | 2011-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| DE602006014812D1 (de) | 2005-04-05 | 2010-07-22 | Allergan Inc | Lostridientoxinaktivität |
| US8796429B2 (en) | 2006-05-31 | 2014-08-05 | Lpath, Inc. | Bioactive lipid derivatives, and methods of making and using same |
| CA2658260A1 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| AU2007272517B2 (en) | 2006-07-11 | 2013-09-26 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells |
| KR101604515B1 (ko) * | 2008-03-14 | 2016-03-17 | 알러간, 인코포레이티드 | 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정 |
| AU2009223161B2 (en) * | 2008-03-14 | 2014-10-30 | Allergan, Inc. | Immuno-based botulinum toxin serotype A activity assays |
| EP2568285B1 (en) * | 2009-03-13 | 2019-12-25 | Allergan, Inc. | Immuno-based retargeted endopeptidase activity assays |
-
2010
- 2010-03-12 EP EP12195253.5A patent/EP2568285B1/en active Active
- 2010-03-12 HU HUE17192861A patent/HUE047067T2/hu unknown
- 2010-03-12 BR BRPI1009115A patent/BRPI1009115A2/pt not_active Application Discontinuation
- 2010-03-12 UA UAA201111973A patent/UA104456C2/uk unknown
- 2010-03-12 KR KR1020177032197A patent/KR101923847B1/ko not_active Expired - Fee Related
- 2010-03-12 PL PL10709360T patent/PL2406629T3/pl unknown
- 2010-03-12 SI SI201031967T patent/SI3281953T1/sl unknown
- 2010-03-12 ES ES17192861T patent/ES2770033T3/es active Active
- 2010-03-12 DK DK17192861.7T patent/DK3281953T3/da active
- 2010-03-12 AU AU2010223912A patent/AU2010223912B2/en not_active Ceased
- 2010-03-12 ES ES10709360.1T patent/ES2440597T3/es active Active
- 2010-03-12 JP JP2011554260A patent/JP5826635B2/ja not_active Expired - Fee Related
- 2010-03-12 PL PL17192861T patent/PL3281953T3/pl unknown
- 2010-03-12 RU RU2011140251/15A patent/RU2543650C2/ru not_active IP Right Cessation
- 2010-03-12 EP EP12196264A patent/EP2570809A1/en not_active Withdrawn
- 2010-03-12 PT PT171928617T patent/PT3281953T/pt unknown
- 2010-03-12 US US12/723,595 patent/US8455203B2/en active Active
- 2010-03-12 WO PCT/US2010/027244 patent/WO2010105236A1/en not_active Ceased
- 2010-03-12 MX MX2011009606A patent/MX2011009606A/es active IP Right Grant
- 2010-03-12 EP EP10709360.1A patent/EP2406629B9/en not_active Revoked
- 2010-03-12 DK DK10709360.1T patent/DK2406629T5/en active
- 2010-03-12 CN CN201080020198.XA patent/CN102422158B/zh not_active Expired - Fee Related
- 2010-03-12 EP EP17192861.7A patent/EP3281953B1/en not_active Not-in-force
- 2010-03-12 SG SG2011065679A patent/SG174353A1/en unknown
- 2010-03-12 MY MYPI2011004314A patent/MY156334A/en unknown
- 2010-03-12 CA CA2753894A patent/CA2753894C/en not_active Expired - Fee Related
- 2010-03-12 KR KR1020117023982A patent/KR101797045B1/ko not_active Expired - Fee Related
-
2011
- 2011-08-22 IL IL214793A patent/IL214793A/en active IP Right Grant
- 2011-09-13 CL CL2011002274A patent/CL2011002274A1/es unknown
-
2013
- 2013-03-13 US US13/801,711 patent/US20130267010A1/en not_active Abandoned
-
2015
- 2015-04-24 US US14/695,938 patent/US9651553B2/en active Active
- 2015-05-05 PH PH12015500992A patent/PH12015500992A1/en unknown
- 2015-10-14 JP JP2015203102A patent/JP6254132B2/ja not_active Expired - Fee Related
-
2017
- 2017-05-12 US US15/593,727 patent/US10345306B2/en active Active
-
2019
- 2019-07-08 US US16/504,870 patent/US10900967B2/en active Active
- 2019-12-31 CY CY20191101368T patent/CY1122573T1/el unknown
-
2021
- 2021-01-25 US US17/157,281 patent/US20210172952A1/en not_active Abandoned
-
2023
- 2023-12-21 US US18/392,925 patent/US20240272160A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012520470A5 (enExample) | ||
| CA2816976A1 (en) | Optogenetic control of reward-related behaviors | |
| Kagias et al. | Members of the NODE (Nanog and Oct4-associated deacetylase) complex and SOX-2 promote the initiation of a natural cellular reprogramming event in vivo | |
| BRPI0714212B8 (pt) | método de produzir uma glicoproteína em uma cultura celular | |
| ES2479542T1 (es) | Métodos y composiciones para su uso en terapias celulares | |
| GB201020995D0 (en) | Biological materials and uses thereof | |
| NO20083266L (no) | Humane anti-IL-23-antistoffer, sammensetninger, fremgangsmater og anvendelser | |
| TR201806812T4 (tr) | Rna-yönlendirmeli hedef dna modifikasyonu için ve rna-yönlendirmeli transkripsiyon modifikasyonu için yöntemler ve bileşimler. | |
| CA2851316C (en) | Genes and proteins for alkanoyl-coa synthesis | |
| CL2012003077A1 (es) | Polipeptido que comprende el decimo dominio de fibronectina tipo iii (10fn3), en donde el dominio 10fn3 se une al dominio 1 o 2 de seroalbumina humana, y donde la vida media del suero del polipéptido en presencia de seroalbumina es al menos 5 veces mayor que en su ausencia; acido nucleico que lo codifica; vector que lo comprende; celula hospedera que lo expresa; composición que lo comprende; y su uso para tratar la diabetes. | |
| NO20080462L (no) | Krystallformer av astaxantin | |
| BR112013010855A2 (pt) | luciferases derivadas de oplophorus, novos substratos de coelenterazina e métodos de uso | |
| BR112012028805A2 (pt) | composições de endorribonuclease e métodos de uso das mesmas. | |
| IN2014CN02906A (enExample) | ||
| CY1110734T1 (el) | Μεθοδος παραγωγης μονιμων ανθρωπινων κυτταρικων σειρων | |
| BRPI0418805A (pt) | construção de recombinante de adenovìrus oncolìtico expressando especificamente um fator imunomodulatório gm-csf em células tumorais e seus usos | |
| WO2007084321A3 (en) | Antibodies to ox-2/cd200 and uses thereof | |
| WO2009126251A3 (en) | Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator | |
| WO2010056831A3 (en) | Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator | |
| CY1118990T1 (el) | Βακτηριακο στελεχος ξενιστης που εκφραζει ανασυνδυασμενη dsbc και εχει μειωμενη ενεργοτητα tsp | |
| MX348152B (es) | Anticuerpo monoclonal humano con especificidad para el virus del dengue serotipo 1 proteina e y sus usos. | |
| FR3034430A1 (fr) | Lignee cellulaire surexprimant l'antigene cd303 humain | |
| EA201990179A1 (ru) | Новый природный белок и его применение | |
| MX2014000322A (es) | Tecnologia de simulacion integrada. | |
| EP2558123C0 (en) | USES AND COMPOSITION FOR INHIBITING TREG CELLS, CONTAINING T-HELPER CELLS AND A CELL LYSATE ENRICHED FOR CHAPERONINS |